Efficacy of BIIB059 in Adults with Systemic Lupus Erythematosus (SLE)

Clinical Trial Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants with Active Systemic Lupus Erythematosus (SLE) Receiving Background Nonbiologic Lupus Standard of Care

National Clinical Trial Number:


Contact Information

Clinical Trial Protocol Description:

This study is being conducted to investigate an experimental drug, BIIB059. The study will determine the effect of the drug in reducing disease activity and inflammation for people with systemic lupus erythematosus (SLE) compared to a placebo group.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are at least 18 years of age. 
  • Have been diagnosed with SLE at least 24 weeks ago.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Meenakshi Jolly, MD, MS

Contact Information

Joshlean Fair

Clinical Trial Location

RUSH University Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more